Serotonin reuptake inhibitors
AssigneeTheravance, Inc.
InventorsEric L. Stangeland, Lori Jean Van Orden, Daisuke Roland Saito
Life of this patent
Estimating the term…
Abstract
In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
Claims18
(canceled)
The method of claim 20, where Y is —CH—.
The method of claim 20, where R1 is selected from —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms, —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms, and —NO2.
The method of claim 20, where R2 is selected from hydrogen and —CN.
The method of claim 20, where R2 is hydrogen.
The method of claim 20, where n is 1.
The method of claim 20, where Q is —NR3SO2R4.
The method of claim 20, where Q is —SO2NR5R6.
15-19. (canceled)
A method of treating a disease selected from pulmonary arterial hypertension, gastrointestinal disorders, cancer, rheumatoid arthritis, osteoarthritis, osteoporosis, and diabetes, comprising administering a therapeutically effective amount of a compound of formula I:
- where:
- Y is —CH— or —N—;
- R1 is selected from halo;
- —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms;
- —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms;
- —C0-1alkylene-phenyl;
- —O—C0-3alkylene-phenyl;
- —SO2—C1-6alkyl;
- —C(O)NH2;
- and —NO2;
- R2 is selected from hydrogen, halo, and —CN;
- n is an integer from 1 to 3;
- Q is selected from —NR3SO2R4 and —SO2NR5R6;
- R3 is selected from hydrogen, —C1-6alkyl, and —C(O)C1-6alkyl;
- R4 is selected from —C1-6alkyl;
- —C1-6cycloalkyl;
- —NR7R8;
- —CH2SO2—C1-6alkyl;
- pyrazole optionally substituted with —CH3;
- triazole;
- morpholine;
- benzoxadiazole;
- and phenyl optionally substituted with R9;
- where R7 and R8 are independently selected from hydrogen and —C1-6alkyl;
- and R9 is selected from —CN, —COOH, —NO2, —C0-2alkylene-O—C1-6alkyl, —C(O)NR7R8, —NR7C(O)—C1-6alkyl, —SO2—C1-6alkyl, —SO2—NR7R8, and a nitrogen-containing heteroaryl optionally substituted with 1 or 2-CH3 groups;
- R5 is selected from hydrogen and —C1-6alkyl;
- and
- R6 is selected from hydrogen, —C1-6alkyl, and benzyl;
- or a pharmaceutically acceptable salt thereof.
A method of treating a patient that is in need of anti-platelet therapy, comprising administering a therapeutically effective amount of a compound of formula I:
- where:
- Y is —CH— or —N—;
- R1 is selected from halo;
- —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms;
- —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms;
- —C0-1alkylene-phenyl;
- —O—C0-3alkylene-phenyl;
- —SO2—C1-6 alkyl;
- —C(O)NH2;
- and —NO2;
- R2 is selected from hydrogen, halo, and —CN;
- n is an integer from 1 to 3;
- Q is selected from —NR3SO2R4 and —SO2NR5R6;
- R3 is selected from hydrogen, —C1-6alkyl, and —C(O)C1-6alkyl;
- R4 is selected from —C1-6alkyl;
- —C1-6cycloalkyl;
- —NR7R8;
- —CH2SO2—C1-6alkyl;
- pyrazole optionally substituted with —CH3;
- triazole;
- morpholine;
- benzoxadiazole;
- and phenyl optionally substituted with R9;
- where R7 and R8 are independently selected from hydrogen and —C1-6alkyl;
- and R9 is selected from —CN, —COOH, —NO2, —C0-2alkylene-O—C1-6alkyl, —C(O)NR7R8, —NR7C(O)—C1-6 alkyl, —SO2—C1-6 alkyl, —SO2—NR7R8, and a nitrogen-containing heteroaryl optionally substituted with 1 or 2-CH3 groups;
- R5 is selected from hydrogen and —C1-6alkyl;
- and
- R6 is selected from hydrogen, —C1-6alkyl, and benzyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.